Skip to content
Biotechnology

Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program

Northway Biotech 3 mins read
  • Media:

ZUG, SWITZERLAND AND VILNIUS, LITHUANIA / ACCESS Newswire / March 4, 2025 / Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis.

Micreos is focused on developing best-in-class targeted therapeutics to precisely target harmful pathogens that cause disease flares to help address significant unmet medical needs in dermatology and oncology.

As part of the partnership, Northway Biotech will apply its significant expertise in biologics manufacturing to develop a scalable GMP production process for Micreos' engineered endolysin technology. The collaboration will also include developing and validating robust analytical methods, cell bank manufacturing, technology scale-up for cGMP Drug Substance generation, and IND/IMPD supporting documentation preparation, to ensure that the production of Micreos' engineered endolysins complies with stringent regulatory standards for clinical trials.

Matt Regan, CEO of Micreos, stated: "This partnership with Northway Biotech marks a significant milestone for Micreos as we advance our engineered endolysins into scalable therapeutics for clinical trials. By developing targeted medicines that address the underlying pathophysiology associated with disease aggravation in conditions such as atopic dermatitis and cutaneous T-Cell lymphoma, and by leveraging Northway's significant manufacturing expertise, we are poised to make a meaningful impact on patient care in areas of great unmet medical need."

Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, highlighted the mutual commitment to high-quality manufacturing: "We are honored to contribute to Micreos' innovative engineered endolysin therapies. With a dedicated and highly experienced team in recombinant protein process development and scale-up, we aim to accelerate Micreos' development by providing cGMP drug substance material available by the end of summer 2024."

André Markmann, PhD, VP of Business Development at Northway Biotech, added: "Micreos' engineered endolysins address critical healthcare challenges. We are excited to support Micreos in advancing their breakthrough therapy into clinical trials at a rapid pace while ensuring the highest standards."

About MEndoB

Micreos' MEndoB is the first-in-class and potentially best-in-class dual-active domain, targeted medicine designed for optimum activity on human skin. It works through targeted enzymatic degradation of the targets cell wall, rapidly killing the harmful pathogen, but without triggering drug resistance or having any off target affects. Micreos' engineering expertise has enhanced drug stability and activity but has also been validated to effectively penetrate biofilms, eliminate dormant & hard to kill pathogenic cells, and potentially deliver synergies with other medications. With demonstrated preclinical efficacy, MEndoB holds significant promise for treating chronic and difficult-to-treat conditions in dermatology and oncology.

About Micreos

Micreos is a preclinical-stage biopharmaceutical company developing highly innovative, targeted therapies as a new way to treat chronic conditions in dermatology and oncology where there is a high unmet medical need. With its advanced engineering platform, Micreos is developing targeted medicines that selectively eliminate harmful pathogens while preserving the beneficial microbiome, paving the way for future indications in dermatology, oncology, and beyond.

For more information, visit www.micreos.com.

About Northway Biotech

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enables rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.

For more information, please visit www.northwaybiotech.com.

Micreos Contact:

Matt Regan
CEO and Board member, Micreos Pharmaceutical AG
m.regan@micreos.com

Northway Biotech Contact:

Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com

Contact Information

Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com

.

SOURCE: Northway Biotech



View the original press release on ACCESS Newswire

More from this category

  • Biotechnology, Business Company News
  • 12/03/2025
  • 09:55
Jane Morgan Management

BlinkLab Commences U.S. Autism Diagnostic Study with First Child Tested

Sydney, Australia – 12 March 2025 | BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”) is pleased to announce that the first patient has been tested in its pivotal U.S. autism diagnostic study, marking the official commencement of the largest digital diagnostic trial for autism in the United States. The trial is designed to validate BlinkLab Dx1, an AI-powered, smartphone-based diagnostic tool that aims to become a critical aid for the early assessment of autism. Highlights First U.S. clinical trial participant successfully tested at PriMED Clinical Research LLC in Dayton, Ohio. The study aims to enroll 100 participants at first, expanding…

  • Contains:
  • Biotechnology, Business Company News
  • 11/03/2025
  • 14:19
Jane Morgan Management

ReNerve (ASX:RNV) Expands in Asian Market with NervAlign® Nerve Cuff(TM) Approval in Thailand and First Sales in Hong Kong

11 March 2025 – Sydney, Australia | ReNerve Limited (ASX:RNV) ("ReNerve" or "the Company") is pleased to announce key milestones in its Asian market expansion, including marketing approval for the NervAlign® Nerve Cuff™ in Thailand, as well as its first hospital stocking order in Hong Kong. These developments strengthen ReNerve’s commercial presence outside the initial market it has entered in the United States, and supports its global growth strategy in solutions for peripheral nerve injury, repair, and regeneration. Highlights NervAlign® Nerve Cuff approved for sale in Thailand, paving the way for commercial rollout in the nation of 70+ million people.…

  • Contains:
  • Biotechnology, Business Company News
  • 28/02/2025
  • 11:39
Jane Morgan Management

LTR Pharma to Present SPONTAN® Clinical Results at Major Upcoming Urological Conference

LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") is pleased to announce that its Chief Scientific and Clinical Advisor, Professor Eric Chung, will present pivotal SPONTAN® clinical trial data at the Urological Society of Australia and New Zealand (USANZ) Annual Scientific Meeting in Perth, from 1 to 4 March 2025. Highlights 470% Faster Absorption: SPONTAN achieves mean maximum plasma concentration in 12 minutes, compared to 56 minutes for oral ED tablets. Lower Dose & Same Efficacy: SPONTAN delivers results with half of the drug dose, maintaining comparable bioavailability and a favourable safety profile. Clinical Validation: These results highlight SPONTAN’s…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.